Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

799.90 +12.68 (+1.61%)
Official Closing Price Updated: 7:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic... 
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
3 Healthcare Stocks to Sell in August Before They Crash & Burn
Investors are looking to the healthcare sector for safe harbor. But these are three healthcare stocks to sell in August 2024. 
Via InvestorPlace
Analyzing Eli Lilly In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Eli Lilly Unusual Options Activity
Via Benzinga
Why Eli Lilly Stock Just Jumped 8%
How fast must Lilly grow to justify a 54.5 P/E ratio? 
Via The Motley Fool
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide. 
Via MarketBeat
Topics ETFs
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space. 
Via The Motley Fool
Eli Lilly & Co. Stocks Elliott Wave Technical Analysis - Friday, August 9
Looking for a top in wave {b} of 4 to then complete the overall correction, knowing we could already have a bottom in Minor wave 4 in place. 
Via Talk Markets
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound, Mounjaro Sales Boom
Drug giant also raises guidance. Lilly stock soared. 
Via Investor's Business Daily
Before the Bell: Eli Lilly Presents its Q2 Results
Before the Bell: Eli Lilly Presents its Q2 Results 
Via Chartmill
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in. 
Via MarketBeat
2 Healthcare Stocks to Buy Hand Over Fist in August
These longtime winners still have a lot to offer. 
Via The Motley Fool
S&P 500 Records Best Session Since January 2023: Investor Sentiment Improves, But Greed Index Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly Shatters Q2 Estimates, Boosts Annual Guidance on Mounjaro and Zepbound Surge
Eli Lilly Shatters Q2 Estimates, Boosts Annual Guidance on Mounjaro and Zepbound Surge 
Via Chartmill
Eli Lilly (LLY) Q2 2024 Earnings Call Transcript
LLY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Dow Jumps Over 500 Points; Eli Lilly Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Eli Lilly And Company Shines In Q2 With $11.30B Revenue, 68% EPS Growth
Eli Lilly and Company has reported a strong financial performance for the second quarter of 2024, with revenue reaching $11.30 billion. 
Via Talk Markets
LLY Stock Alert: Why Are Eli Lilly Shares Surging Today?
Eli Lilly's growth should accelerate now that shortages of its GLP-1 drugs are resolved, but competitors are coming. 
Via InvestorPlace
Mounjaro Maker Eli Lilly's Bumper Q2 Earnings Exceeds Estimates, Hikes Outlook Again On Strong Diabetes And Weight Loss Drugs Sales
Eli Lilly's Q2 revenue surged 36% year-over-year to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and other key drugs. The company raised its 2024 sales and EPS guidance, citing improved... 
Via Benzinga
Bears Betting Against Nvidia And Eli Lilly For 'Easy Money,' Says Jim Cramer: 'Those Are The Two Keys To This Market And Don't You Know It'
Jim Cramer has issued a warning about the bearish pressure on NVIDIA Corp. and Eli Lilly and Co, stating that these two companies are crucial to the market's performance. 
Via Benzinga
US Stocks Decline As SMCI's Margin Miss Brings Nvidia And Other AI Stocks Under Pressure: Investor Sentiment Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly, US Foods And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings
Eli Lilly (LLY) reports Q2 earnings on Thursday with expected EPS of $2.70 and $9.9B in revenues. Stock shows bearish trend but analysts predict 15% upside. 
Via Benzinga
What's Going On With Eli Lilly And Company Shares Wednesday?
Eli Lilly is anticipated to release earnings 2024 fiscal year earnings on Thursday before the market opens. 
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.